Verition Fund Management LLC lowered its position in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get Rating) by 68.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,396 shares of the company's stock after selling 5,242 shares during the period. Verition Fund Management LLC's holdings in Biohaven Pharmaceutical were worth $284,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. US Bancorp DE lifted its position in Biohaven Pharmaceutical by 19.1% in the first quarter. US Bancorp DE now owns 586 shares of the company's stock valued at $70,000 after purchasing an additional 94 shares during the period. Victory Capital Management Inc. lifted its position in Biohaven Pharmaceutical by 6.4% in the first quarter. Victory Capital Management Inc. now owns 2,564 shares of the company's stock valued at $229,000 after purchasing an additional 155 shares during the period. Washington Trust Advisors Inc. lifted its position in Biohaven Pharmaceutical by 24.6% in the first quarter. Washington Trust Advisors Inc. now owns 810 shares of the company's stock valued at $96,000 after purchasing an additional 160 shares during the period. Canton Hathaway LLC lifted its position in Biohaven Pharmaceutical by 3.5% in the first quarter. Canton Hathaway LLC now owns 5,860 shares of the company's stock valued at $695,000 after purchasing an additional 200 shares during the period. Finally, Level Four Advisory Services LLC lifted its position in Biohaven Pharmaceutical by 3.0% in the first quarter. Level Four Advisory Services LLC now owns 6,947 shares of the company's stock valued at $824,000 after purchasing an additional 204 shares during the period. Institutional investors and hedge funds own 78.19% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BHVN shares. Piper Sandler downgraded shares of Biohaven Pharmaceutical from an "overweight" rating to a "neutral" rating and set a $149.00 price target for the company. in a research report on Thursday, August 18th. Wedbush downgraded shares of Biohaven Pharmaceutical from an "outperform" rating to a "neutral" rating and set a $148.50 price target for the company. in a research report on Monday, August 8th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $157.17.

Biohaven Pharmaceutical Price Performance

Biohaven Pharmaceutical (NYSE:BHVN – Get Rating) last issued its quarterly earnings data on Friday, August 5th. The company reported ($6.21) earnings per share for the quarter, missing analysts' consensus estimates of ($2.79) by ($3.42). The firm had revenue of $215.08 million for the quarter, compared to analyst estimates of $209.33 million. On average, equities analysts expect that Biohaven Pharmaceutical Holding Company Ltd. will post -13.48 earnings per share for the current fiscal year.

Insider Transactions at Biohaven Pharmaceutical

In other Biohaven Pharmaceutical news, Director Gregory Bailey acquired 38,000 shares of the company's stock in a transaction dated Friday, August 19th. The stock was acquired at an average cost of $148.04 per share, with a total value of $5,625,520.00. Following the purchase, the director now directly owns 2,583,658 shares in the company, valued at approximately $382,484,730.32. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 12.40% of the company's stock.

About Biohaven Pharmaceutical

(Get Rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

See Also

• Get a free copy of the StockNews.com research report on Biohaven Pharmaceutical (BHVN)
• Can Caterpillar Claw Higher in a Falling Market?
• Is Dave & Buster's Immune to High Inflation and Lower Spending?
• Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
• Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
• MarketBeat: Week in Review 9/19 – 9/23

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.